Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

MLA

Harrison, Claire N., et al. “Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib (SIMPLIFY 2): A Randomised, Open-Label, Phase 3 Trial.” The Lancet. Haematology, vol. 5, no. 2, Feb. 2018, pp. e73–81. EBSCOhost, https://doi.org/10.1016/S2352-3026(17)30237-5.

APA

Harrison, C. N., Vannucchi, A. M., Platzbecker, U., Cervantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E. F., Dong, H., Kawashima, J., Maltzman, J. D., Kiladjian, J.-J., & Verstovsek, S. (2018). Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. The Lancet. Haematology, 5(2), e73–e81. https://doi.org/10.1016/S2352-3026(17)30237-5

Chicago

Harrison, Claire N, Alessandro M Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, et al. 2018. “Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib (SIMPLIFY 2): A Randomised, Open-Label, Phase 3 Trial.” The Lancet. Haematology 5 (2): e73–81. doi:10.1016/S2352-3026(17)30237-5.